GlobeNewsWire
13 Sept 2026, 14:20 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Capricor Therapeutics allegedly changed its statistical analysis plan for the cell therapy Deramiocel without prior FDA agreement before resubmitting its Biologics License Application (BLA). — Unauthorized changes to clinical data analysis plans significantly increase the risk of FDA rejection, which is a critical binary event for biotech companies.
-0.80A securities class action lawsuit claims that Capricor's positive statements regarding its business and prospects were misleading due to regulatory risks surrounding Deramiocel. — Lawsuits create legal overhang and reputational risk, though the impact is secondary to the underlying regulatory failure claimed.
-0.40The lead plaintiff deadline for the Capricor Therapeutics securities class action is September 28, 2026. — This is a procedural legal deadline with minimal direct impact on stock price or company fundamentals.
-0.10Which stocks this story touches
Continue reading
5 related stories
Search tags
The company is facing a securities class action lawsuit alleging materially false and misleading statements regarding FDA regulatory processes.
The company is mentioned as the target of a securities class action notice from the Rosen Law Firm.
The company is mentioned as the target of a securities class action notice from the Rosen Law Firm.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2h ago
